These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12232712)

  • 1. [F-18 FDG positron emission tomography in diagnosis and follow-up of patients with musculoskeletal tumors].
    Dobrowolskij D; Niggemeyer O; Jenicke L; Bruns J
    Orthopade; 2002 Sep; 31(9):921-9. PubMed ID: 12232712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring bone and soft-tissue tumors after carbon-ion radiotherapy using ¹⁸F-FDG positron emission tomography: a retrospective cohort study.
    Yanagawa T; Saito K; Kiyohara H; Ohno T; Nakano T; Takagishi K
    Radiat Oncol; 2015 Dec; 10():259. PubMed ID: 26691334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma.
    el-Zeftawy H; Heiba SI; Jana S; Rosen G; Salem S; Santiago JF; Abdel-Dayem HM
    Cancer Biother Radiopharm; 2001 Feb; 16(1):37-46. PubMed ID: 11279796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas.
    Lucas JD; O'Doherty MJ; Wong JC; Bingham JB; McKee PH; Fletcher CD; Smith MA
    J Bone Joint Surg Br; 1998 May; 80(3):441-7. PubMed ID: 9619933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of F-18 FDG PET and 201Tl scintigraphy for detection of primary malignant bone and soft-tissue tumors.
    Yamamoto Y; Kawaguchi Y; Kawase Y; Maeda Y; Nishiyama Y
    Clin Nucl Med; 2011 Apr; 36(4):290-4. PubMed ID: 21368603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
    Schuetze SM; Rubin BP; Vernon C; Hawkins DS; Bruckner JD; Conrad EU; Eary JF
    Cancer; 2005 Jan; 103(2):339-48. PubMed ID: 15578712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis with (18)F-FDG PET scan after larynx preservation by primary radiochemotherapy].
    Dietz A; Rudat V; Harms W; Jungehülsing M; Dollner R; Henze M
    HNO; 2004 Jan; 52(1):38-44. PubMed ID: 14740113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
    Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
    J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
    Iagaru A; Masamed R; Chawla SP; Menendez LR; Fedenko A; Conti PS
    Clin Nucl Med; 2008 Jan; 33(1):8-13. PubMed ID: 18097248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
    Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
    Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
    J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG.
    Nakamoto Y; Osman M; Wahl RL
    Clin Nucl Med; 2003 Apr; 28(4):302-7. PubMed ID: 12642709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-PET for evaluating musculoskeletal tumors: a review.
    Aoki J; Endo K; Watanabe H; Shinozaki T; Yanagawa T; Ahmed AR; Takagishi K
    J Orthop Sci; 2003; 8(3):435-41. PubMed ID: 12768492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
    Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
    Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients.
    Kushner BH; Yeung HW; Larson SM; Kramer K; Cheung NK
    J Clin Oncol; 2001 Jul; 19(14):3397-405. PubMed ID: 11454888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases.
    Kao CH; Hsieh JF; Tsai SC; Ho YJ; Yen RF
    Anticancer Res; 2000; 20(3B):2189-92. PubMed ID: 10928175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correlation of FDG-PET and MRI/CT with histopathology in primary diagnosis, lymph node staging and diagnosis of recurrency of head and neck cancer].
    Pöpperl G; Lang S; Dagdelen O; Jäger L; Tiling R; Hahn K; Tatsch K
    Rofo; 2002 Jun; 174(6):714-20. PubMed ID: 12063600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
    De Potter T; Flamen P; Van Cutsem E; Penninckx F; Filez L; Bormans G; Maes A; Mortelmans L
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):525-9. PubMed ID: 11914891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.